Renier J. Brentjens
Built one of the first CD19 CAR-T programmes and invented 'armoured' CAR-T cells that secrete cytokines.
Developed the 19-28z CAR at MSK and led its first leukaemia trials before moving to Roswell Park in 2021, where he develops IL-18 and IL-12 armoured CARs for solid tumours.
| Title | Journal | Year |
|---|---|---|
| CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia | Science Translational Medicine | 2013 |
Pages like this
not linked directly; found by shared links- PersonJae H. Park
Shares CD19, Acute lymphoblastic leukaemia, CAR-T cell therapy.
- TrialFELIX
Shares CD19, Acute lymphoblastic leukaemia, CAR-T cell therapy.
- PersonChristine E. Brown
Shares Armoured, logic-gated & next-gen CARs, CAR-T cell therapy.
- PersonNirali N. Shah
Shares CD19, Acute lymphoblastic leukaemia, CAR-T cell therapy.
- ProductBrexucabtagene autoleucel
Shares CD19, Acute lymphoblastic leukaemia, CAR-T cell therapy.
- TrialTRANSCEND CLL 004
Shares CD19, CAR-T cell therapy.
- TrialELIANA
Shares CD19, Acute lymphoblastic leukaemia, CAR-T cell therapy.
- PersonStanley R. Riddell
Shares CD19, Acute lymphoblastic leukaemia, CAR-T cell therapy.